Prelude Capital Management, LLC Vericel Corp Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$7.25 - $19.22 $58,000 - $153,760	-8,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $110,160 - $153,600	8,000 New	8,000 $139,000
Q2 2019 Aug 14, 2019	SELL	$15.01 - $18.89 $424,978 - $534,832	-28,313 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.23 - $20.29 $5,794 - $7,243	357 Added 1.28%	28,313 $496,000
Q4 2018 Feb 14, 2019	BUY	$10.77 - $18.44 $83,047 - $142,190	7,711 Added 38.09%	27,956 $486,000
Q3 2018 Nov 14, 2018	BUY	$9.1 - $14.8 $37,965 - $61,745	4,172 Added 25.96%	20,245 $286,000
Q2 2018 Aug 14, 2018	BUY	$9.6 - $14.6 $8,640 - $13,140	900 Added 5.93%	16,073 $156,000
Q1 2018 May 15, 2018	BUY	$5.7 - $12.3 $86,486 - $186,627	15,173 New	15,173 $151,000

277

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.73B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.